Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry

Rombouts, Anouk J.; Hugen, Niek; Verhoeven, Rob H.; Kuiper, Josephina G.; Poortmans, Philip M.; de Wilt, Johannes H.; Nagtegaal, Iris D.

doi:10.1016/J.RADONC.2019.06.010

Title

Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry

Author

Rombouts, Anouk J.

Hugen, Niek

Verhoeven, Rob H.

Kuiper, Josephina G.

Poortmans, Philip M.

de Wilt, Johannes H.

Nagtegaal, Iris D.

Abstract

Background and purpose: The aim of this study was to assess the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on tumor response to preoperative chemoradiation for rectal cancer. Materials and methods: Data on patients who received chemoradiation prior to surgery for rectal cancer between 2010 and 2015 were retrieved from linkage between the PHARMO Database Network, Dutch Pathology Registry and Netherlands Cancer Registry. Pathological complete response rates (pCR) were compared between patients who did or did not use ACEIs/ARBs during treatment. Multivariable analysis was performed using logistic regression. Results: Out of 345 patients, 92 patients (26.7%) used ACEIs/ARBs during treatment. Median age was 65 years (range 30-85). Older and male patients were more likely to use ACEIs/ARBs. pCR (ypT0N0) was observed in 17.4% of patients using ACEIs/ARBs compared to 14.6% of patients who did not use ACEIs/ARBs (p = 0.595). A good response (ypT0-1N0) was observed in 21.7% of ACEIs/ARBs patients vs. 19.4% of patients who did not use ACEIs/ARBs (p = 0.724). Multivariable analysis, taking into account background variables and co-medication, showed increased pCR in patients using beta-blockers (odds ratio 2.3, 95% confidence interval 1.0-5.4). Conclusion: In this retrospective cohort, the use of ACEIs/ARBs was not associated with tumor response to preoperative chemoradiation in rectal cancer patients. Thereby, the suggested potentiating effect of ACEIS/ARBs could not be confirmed in our study. Further research could be directed to investigate a possible benefit of beta-blockers or other anti-hypertensive drugs. (C) 2019 Elsevier B.V. All rights reserved.

Language

English

Source (journal)

Radiotherapy and oncology. - Amsterdam

Publication

Amsterdam : 2019

ISSN

0167-8140

DOI

10.1016/J.RADONC.2019.06.010

Volume/pages

138 (2019) , p. 86-92